Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Kreter

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Pharmacotherapy|January 1, 1991
Abuse of computer graphicsB Kreter
Clinical Therapeutics|January 1, 1992
Cost-analysis of imipenem-cilastatin monotherapy compared with clindamycin+aminoglycoside combination therapy for treatment of serious lower respiratory, intra-abdominal, gynecologic, and urinary tract infectionsB Kreter
The Journal of Thoracic and Cardiovascular Surgery|September 1, 1992
Antibiotic prophylaxis for cardiothoracic operations. Meta-analysis of thirty years of clinical trialsB Kreter, M Woods
DICP : the Annals of Pharmacotherapy|April 1, 1990
Aztreonam adverse reactionsT Fekete, L Marcelo, B Kreter
Clinical Therapeutics|January 1, 1992
Efficacy and tolerability of imipenem-cilastatin versus clindamycin+gentamicin for serious pelvic infectionsJ W Larsen, K Gabel-Hughes, B Kreter
Diagnostic Microbiology and Infectious Disease|April 1, 1994
A comparison of serial plate agar dilution, Bauer-Kirby disk diffusion, and the Vitek AutoMicrobic system for the determination of susceptibilities of Klebsiella spp., Enterobacter spp., and Pseudomonas aeruginosa to ten antimicrobial agentsT Fekete, H Tumah, J Woodwell, et al.
The Journal of Infectious Diseases|March 1, 1989
The role of the pharmacist in antimicrobial agent therapyS L Barriere, M N Dudley, S F Kowalsky, et al.
The Journal of Antimicrobial Chemotherapy|September 3, 1999
Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection GroupR L Nichols, D R Graham, S L Barriere, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Pharmacotherapy|January 1, 1991
Abuse of computer graphicsB Kreter
Clinical Therapeutics|January 1, 1992
Cost-analysis of imipenem-cilastatin monotherapy compared with clindamycin+aminoglycoside combination therapy for treatment of serious lower respiratory, intra-abdominal, gynecologic, and urinary tract infectionsB Kreter
The Journal of Thoracic and Cardiovascular Surgery|September 1, 1992
Antibiotic prophylaxis for cardiothoracic operations. Meta-analysis of thirty years of clinical trialsB Kreter, M Woods
DICP : the Annals of Pharmacotherapy|April 1, 1990
Aztreonam adverse reactionsT Fekete, L Marcelo, B Kreter
Clinical Therapeutics|January 1, 1992
Efficacy and tolerability of imipenem-cilastatin versus clindamycin+gentamicin for serious pelvic infectionsJ W Larsen, K Gabel-Hughes, B Kreter
Diagnostic Microbiology and Infectious Disease|April 1, 1994
A comparison of serial plate agar dilution, Bauer-Kirby disk diffusion, and the Vitek AutoMicrobic system for the determination of susceptibilities of Klebsiella spp., Enterobacter spp., and Pseudomonas aeruginosa to ten antimicrobial agentsT Fekete, H Tumah, J Woodwell, et al.
The Journal of Infectious Diseases|March 1, 1989
The role of the pharmacist in antimicrobial agent therapyS L Barriere, M N Dudley, S F Kowalsky, et al.
The Journal of Antimicrobial Chemotherapy|September 3, 1999
Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection GroupR L Nichols, D R Graham, S L Barriere, et al.
Pageof 1